SQI Diagnostics May Seek Merger or Sale | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SQI Diagnostics today said that it has established a special committee to review strategic alternatives for the firm, which could include a possible merger or sale.

SQI said that the special committee was formed to "review interest from a number of parties relating to a possible merger or sale of the company." It also said that it will continue to explore other alternatives, such as strategic alliances.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.